人表皮生长因子受体2作为癌症干细胞靶点 - Suppr

HER2 as a cancer stem-cell target.

作者信息

Roesler Rafael, Cornelio Daniela Baumann, Abujamra Ana Lucia, Schwartsmann Gilberto

出版信息

Lancet Oncol. 2010 Mar;11(3):225-6. doi: 10.1016/S1470-2045(09)70404-8.

DOI:10.1016/S1470-2045(09)70404-8

PMID:20202610

Abstract

摘要

相似文献

HER2 as a cancer stem-cell target.

Lancet Oncol. 2010 Mar;11(3):225-6. doi: 10.1016/S1470-2045(09)70404-8.

The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.

Oncologist. 2004;9 Suppl 3:1-3. doi: 10.1634/theoncologist.9-suppl_3-1.

Targeting alternative pathways in HER2-positive breast cancer.

Oncology (Williston Park). 2010 Apr 30;24(5):415-6.

[Her2 positive breast cancer: practices].

Bull Cancer. 2011 Feb;98(2):154-63.

HER2-positive breast cancer: beyond trastuzumab.

Oncology (Williston Park). 2010 Apr 30;24(5):410-5.

Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.

Cancer Treat Res. 2009;151:197-215. doi: 10.1007/978-0-387-75115-3_13.

[Anti-HER2 therapy for breast cancer--an added increasing therapeutic option].

Gan To Kagaku Ryoho. 2010 Dec;37(13):2845-9.

[The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].

Med Clin (Barc). 2013 Aug 17;141(4):176-80. doi: 10.1016/j.medcli.2013.04.008. Epub 2013 Jun 27.

HER2 targeted therapy in breast cancer...beyond Herceptin.

Rev Endocr Metab Disord. 2007 Sep;8(3):269-77. doi: 10.1007/s11154-007-9040-6.

Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.

Ann Oncol. 2002 Jan;13(1):8-9. doi: 10.1093/annonc/mdf092.

引用本文的文献

STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening.

J Biomed Sci. 2018 Aug 2;25(1):60. doi: 10.1186/s12929-018-0456-y.

BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells.

Oncotarget. 2017 May 23;8(21):35019-35032. doi: 10.18632/oncotarget.16558.

Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.

Oncotarget. 2015 Oct 20;6(32):32317-38. doi: 10.18632/oncotarget.6094.

Stem Cell Differentiation Stage Factors from Zebrafish Embryo: A Novel Strategy to Modulate the Fate of Normal and Pathological Human (Stem) Cells.

Curr Pharm Biotechnol. 2015;16(9):782-92. doi: 10.2174/1389201016666150629102825.

The mitotic kinase Aurora--a promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα(+) breast cancer cells.

Oncogene. 2014 Jan 30;33(5):599-610. doi: 10.1038/onc.2012.628. Epub 2013 Jan 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

HER2 as a cancer stem-cell target.

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献